CGCN GROUP, LLC lobbying for EMERGENT BIOSOLUTIONS INC.

Filing 1st Quarter - Report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 1

HR 1968
Full-Year Continuing Appropriations and Extensions Act, 2025

Lobbying activity 4

Budget/Appropriations

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY25 and FY26; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26; NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025.

Disaster Planning/Emergencies

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY25 and FY26; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26; NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025.

Health Issues

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY25 and FY26; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26; NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025.

Homeland Security

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY25 and FY26; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26; NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025.